348 related articles for article (PubMed ID: 30922043)
1. Continuous subcutaneous apomorphine monotherapy in Parkinson's disease.
Papuć E; Trzciniecka O; Rejdak K
Ann Agric Environ Med; 2019 Mar; 26(1):133-137. PubMed ID: 30922043
[TBL] [Abstract][Full Text] [Related]
2. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.
De Gaspari D; Siri C; Landi A; Cilia R; Bonetti A; Natuzzi F; Morgante L; Mariani CB; Sganzerla E; Pezzoli G; Antonini A
J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):450-3. PubMed ID: 16543520
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
4. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
5. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.
Pahwa R; Koller WC; Trosch RM; Sherry JH;
J Neurol Sci; 2007 Jul; 258(1-2):137-43. PubMed ID: 17466338
[TBL] [Abstract][Full Text] [Related]
7. Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.
Elia AE; Dollenz C; Soliveri P; Albanese A
Eur J Neurol; 2012 Jan; 19(1):76-83. PubMed ID: 21645174
[TBL] [Abstract][Full Text] [Related]
8. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
Manson AJ; Turner K; Lees AJ
Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
[TBL] [Abstract][Full Text] [Related]
9. Apomorphine-subcutaneous--Bertek/Britannia.
Drugs R D; 2004; 5(4):211-2. PubMed ID: 15230626
[TBL] [Abstract][Full Text] [Related]
10. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
Stacy M; Silver D
Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
[TBL] [Abstract][Full Text] [Related]
11. Continuous subcutaneous apomorphine in advanced Parkinson's disease patients treated with deep brain stimulation.
Sesar Á; Fernández-Pajarín G; Ares B; Relova JL; Arán E; Rivas MT; Gelabert-González M; Castro A
J Neurol; 2019 Mar; 266(3):659-666. PubMed ID: 30617907
[TBL] [Abstract][Full Text] [Related]
12. Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients.
Sesar Á; Fernández-Pajarín G; Ares B; Rivas MT; Castro A
J Neurol; 2017 May; 264(5):946-954. PubMed ID: 28364292
[TBL] [Abstract][Full Text] [Related]
13. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.
Bhidayasiri R; Chaudhuri KR; LeWitt P; Martin A; Boonpang K; van Laar T
Clin Neuropharmacol; 2015; 38(3):89-103. PubMed ID: 25970277
[TBL] [Abstract][Full Text] [Related]
14. [Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations].
Castaño B; Mateo D; Giménez-Roldán S
Neurologia; 2007 Apr; 22(3):133-7. PubMed ID: 17364250
[TBL] [Abstract][Full Text] [Related]
15. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
Colzi A; Turner K; Lees AJ
J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
[TBL] [Abstract][Full Text] [Related]
16. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
[TBL] [Abstract][Full Text] [Related]
17. Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications.
Drapier S; Gillioz AS; Leray E; Péron J; Rouaud T; Marchand A; Vérin M
Parkinsonism Relat Disord; 2012 Jan; 18(1):40-4. PubMed ID: 21890396
[TBL] [Abstract][Full Text] [Related]
18. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.
Martinez-Martin P; Reddy P; Katzenschlager R; Antonini A; Todorova A; Odin P; Henriksen T; Martin A; Calandrella D; Rizos A; Bryndum N; Glad A; Dafsari HS; Timmermann L; Ebersbach G; Kramberger MG; Samuel M; Wenzel K; Tomantschger V; Storch A; Reichmann H; Pirtosek Z; Trost M; Svenningsson P; Palhagen S; Volkmann J; Chaudhuri KR
Mov Disord; 2015 Apr; 30(4):510-6. PubMed ID: 25382161
[TBL] [Abstract][Full Text] [Related]
19. Apomorphine: an underutilized therapy for Parkinson's disease.
Poewe W; Wenning GK
Mov Disord; 2000 Sep; 15(5):789-94. PubMed ID: 11009181
[TBL] [Abstract][Full Text] [Related]
20. [Candidate patient for treatment with continuous apomorphine infusion].
Martí MJ; Kulisevsky J
Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
